Bakker N P, Van Besouw N, Groenestein R, Jonker M, Hart L A
Department of Chronic and Infectious Diseases, TNO Medical Biological Laboratory, Rijswijk, The Netherlands.
Clin Exp Immunol. 1993 Sep;93(3):318-22. doi: 10.1111/j.1365-2249.1993.tb08179.x.
The influence of cyclosporin A (CsA) on type II collagen-induced arthritis (CIA) in the rhesus monkey has been investigated. CsA was administered subcutaneously in a dose of 25 mg/kg per day during 9-18 days and additionally 12.5 mg/kg per day for 7 days. At this dosing regime no significant alterations of haematologic parameters were found, indicating that the toxicity of CsA was negligible. Administration of CsA after onset of arthritis had no beneficial effect, but when given between immunization and manifestation of clinical symptoms, CIA could be prevented completely. Moreover, these monkeys became resistant to the disease, because no arthritic activity could be observed upon a booster immunization with type II collagen (CII). The suppression of disease by CsA is reflected in reduced antibody levels to CII.
已经研究了环孢素A(CsA)对恒河猴II型胶原诱导性关节炎(CIA)的影响。在9至18天期间,以每天25mg/kg的剂量皮下注射CsA,并在接下来的7天里额外每天注射12.5mg/kg。在这种给药方案下,未发现血液学参数有明显变化,这表明CsA的毒性可忽略不计。在关节炎发作后给予CsA没有有益效果,但在免疫和临床症状出现之间给予时,CIA可以完全预防。此外,这些猴子对该疾病产生了抗性,因为在用II型胶原(CII)进行加强免疫时未观察到关节炎活动。CsA对疾病的抑制作用体现在对CII的抗体水平降低。